Literature DB >> 11657394

Modified informed consent in a viral seroprevalence study in the Caribbean.

Cheryl Cox, CNL Macpherson.   

Abstract

An unlinked seroprevalence study of HIV and other viruses was conducted on pregnant women on the Caribbean island of Grenada in 1994. Investigators were from both the developed world and the Grenadian Ministry of Health (MOH). There was then no board on Grenada to protect research subjects or review ethical aspects of studies. Nurses from the MOH were asked to verbally inform their patients about the study, and request that patients become subjects of the study and give blood for screening. If consent was given nurses took blood and administered a survey about each subjects' knowledge of HIV transmission routes. Nurses shared a spoken dialect and cultural heritage with prospective subjects and were probably more effective than foreign researchers at informing subjects. Informed consent was obtained with a simplified consent form supplemented with conversation with each prospective research subject. Facilitating discussion between people with common cultural backgrounds helps apply the Western approach to informed consent to communites in the developing world. Researchers must disclose all information to nurses or other mediators, and ensure that nurses disclose as much information as possible to prospective subjects. So modified, informed consent maintains respect for persons and becomes applicable and relevant to various cultures.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach; Health Care and Public Health

Mesh:

Year:  1996        PMID: 11657394     DOI: 10.1111/j.1467-8519.1996.tb00121.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  2 in total

1.  Research ethics committees: a regional approach.

Authors:  C C Macpherson
Journal:  Theor Med Bioeth       Date:  1999-04

2.  The battering of informed consent.

Authors:  M Kottow
Journal:  J Med Ethics       Date:  2004-12       Impact factor: 2.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.